[Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].
Seissler
J
J
Diabetes-Zentrum Medizinische Klinik, Innenstadt Klinikum der LMU München. jochen.seissler@med.uni-muenchen.de
D000284:Administration, Oral; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D000077285:Rimonabant; D014688:Venoms / Q000009:adverse effects / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D010455:Peptides; D010880:Piperidines; D011720:Pyrazoles; D014688:Venoms; D000077270:Exenatide; D000077285:Rimonabant